REPLAGAL® is the commercial brand name of Agalsidase Alfa Concentrated Solution for Infusion, developed by Shire Human Genetic Therapies AB and manufactured by Vetter Pharma-Fertigung GmbH & Co.KG, distributed by Takeda. It is a recombinant human alpha-galactosidase enzyme replacement therapy.…
MOUNJARO® is the commercial brand name of Tirzepatide Injection, developed by Eli Lilly and Company. It is a once-weekly dual GLP‑1 and GIP receptor agonist for subcutaneous injection. It activates two intestinal hormone receptors simultaneously to suppress glucagon release, slow…
Invokana® is the commercial brand name of Canagliflozin Tablets, co-developed by Merck and Janssen. It is an oral sodium-glucose cotransporter 2 inhibitor. It inhibits glucose reabsorption in renal tubules to boost glycosuria excretion, lowering blood glucose independent of pancreatic beta…
STEGLATRO® is the commercial brand name of Ertugliflozin Tablets, developed by MSD. It is an oral sodium-glucose cotransporter 2 inhibitor. It blocks glucose reabsorption in renal tubules to promote urinary glucose excretion, lowering blood sugar independent of pancreatic beta cell…
Lyxumia® is the international commercial brand name of Lixisenatide Injection, developed by Sanofi. It is a short-acting once-daily GLP‑1 receptor agonist for subcutaneous injection. It targets postprandial blood glucose by delaying gastric emptying and suppressing meal-stimulated glucagon secretion, delivering glucose-dependent…
Victoza® is the commercial brand name of Liraglutide Injection, developed by Novo Nordisk. It is a once-daily injectable GLP‑1 receptor agonist. It activates GLP‑1 receptors to inhibit glucagon release, delay gastric emptying and reduce appetite, lowering blood glucose in a…
Trulicity® is the commercial brand name of Dulaglutide Injection, developed by Eli Lilly and Company. It is a long-acting GLP‑1 receptor agonist administered once weekly subcutaneously. It activates GLP‑1 receptors to suppress glucagon secretion, slow gastric emptying, reduce food intake…
TENELIA® is the commercial brand name of Teneligliptin Hydrobromide Tablets, developed by Mitsubishi Tanabe Pharma Corporation. It is a long-acting oral DPP-4 inhibitor. It inhibits dipeptidyl peptidase 4 to prolong the activity of endogenous GLP-1 and GIP, regulating blood glucose…
Chuanbeiqing® is the domestic commercial brand name of Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution, developed by Jumpcan Pharmaceutical Group Co., Ltd. As an isotonic bowel cleanser, the compound sulfate salts create high osmotic pressure inside intestines,…
Lijingqing® is the domestic commercial brand name of Ursodeoxycholic Acid Oral Suspension, developed by CYNogen Bio. It is a hydrophilic natural bile acid preparation. It reduces the accumulation of toxic hydrophobic bile acids in hepatocytes, protects liver and bile duct…